These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 35040284)

  • 1. Racial and ethnic variation in multigene panel testing in a cohort of BRCA1/2-negative individuals who had genetic testing in a large urban comprehensive cancer center.
    Tatineni S; Tarockoff M; Abdallah N; Purrington KS; Assad H; Reagle R; Petrucelli N; Simon MS
    Cancer Med; 2022 Mar; 11(6):1465-1473. PubMed ID: 35040284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial and ethnic variation in BRCA1 and BRCA2 genetic test results among individuals referred for genetic counseling at a large urban comprehensive cancer center.
    Abdallah N; Purrington KS; Tatineni S; Assad H; Petrucelli N; Simon MS
    Cancer Causes Control; 2023 Feb; 34(2):141-149. PubMed ID: 36370215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disparate Rates of Germline Variants in Cancer Predisposition Genes in African American/Black Compared With Non-Hispanic White Individuals Between 2015 and 2022.
    Wyatt Castillo RB; Nielsen SM; Chen E; Heald B; Ellsworth RE; Esplin ED; Tomlinson GE
    JCO Precis Oncol; 2024 Jul; 8():e2300715. PubMed ID: 38991178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
    Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
    Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial and Ethnic Differences in Multigene Hereditary Cancer Panel Test Results for Women With Breast Cancer.
    Yadav S; LaDuca H; Polley EC; Hu C; Niguidula N; Shimelis H; Lilyquist J; Na J; Lee KY; Gutierrez S; Yussuf A; Hart SN; Davis BT; Chao EC; Pesaran T; Goldgar DE; Dolinsky JS; Couch FJ
    J Natl Cancer Inst; 2021 Oct; 113(10):1429-1433. PubMed ID: 33146377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
    Kurian AW; Ward KC; Abrahamse P; Bondarenko I; Hamilton AS; Deapen D; Morrow M; Berek JS; Hofer TP; Katz SJ
    J Clin Oncol; 2021 May; 39(15):1631-1640. PubMed ID: 33560870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
    Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
    Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Multigene Panel Testing Identifies Racial and Ethnic Differences in Germline Pathogenic Variants Among Patients With Early-Onset Colorectal Cancer.
    Seagle HM; Keller SR; Tavtigian SV; Horton C; Holowatyj AN
    J Clin Oncol; 2023 Sep; 41(26):4279-4289. PubMed ID: 37319387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective Cohort Study on the Limitations of Direct-to-Consumer Genetic Screening in Hereditary Breast and Ovarian Cancer.
    Desai NV; Barrows ED; Nielsen SM; Hatchell KE; Anderson MJ; Haverfield EV; Herrera B; Esplin ED; Lucassen A; Tung NM; Isaacs C
    JCO Precis Oncol; 2023 Aug; 7():e2200695. PubMed ID: 37535880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center.
    Chapman-Davis E; Zhou ZN; Fields JC; Frey MK; Jordan B; Sapra KJ; Chatterjee-Paer S; Carlson AD; Holcomb KM
    J Gen Intern Med; 2021 Jan; 36(1):35-42. PubMed ID: 32720237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disparities in cancer genetics care by race/ethnicity among pan-cancer patients with pathogenic germline variants.
    Liu YL; Maio A; Kemel Y; Salo-Mullen EE; Sheehan M; Tejada PR; Trottier M; Arnold AG; Fleischut MH; Latham A; Carlo MI; Murciano-Goroff YR; Walsh MF; Mandelker D; Mehta N; Bandlamudi C; Arora K; Zehir A; Berger MF; Solit DB; Aghajanian C; Diaz LA; Robson ME; Brown CL; Offit K; Hamilton JG; Stadler ZK
    Cancer; 2022 Nov; 128(21):3870-3879. PubMed ID: 36041233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.
    Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY
    Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Contribution of Next-Generation Sequencing Multigene Panel Testing for BRCA Negative High-Risk Patients With Breast Cancer.
    Ece Solmaz A; Yeniay L; Gökmen E; Zekioğlu O; Haydaroğlu A; Bilgen I; Özkınay F; Onay H
    Clin Breast Cancer; 2021 Dec; 21(6):e647-e653. PubMed ID: 33980423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing.
    Giri VN; Hartman R; Pritzlaff M; Horton C; Keith SW
    JCO Precis Oncol; 2022 May; 6(1):e2200234. PubMed ID: 35666082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing.
    Dominguez-Valentin M; Nakken S; Tubeuf H; Vodak D; Ekstrøm PO; Nissen AM; Morak M; Holinski-Feder E; Holth A; Capella G; Davidson B; Evans DG; Martins A; Møller P; Hovig E
    Sci Rep; 2019 Dec; 9(1):18555. PubMed ID: 31811167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occurrence of variants of unknown clinical significance in genetic testing for hereditary breast and ovarian cancer syndrome and Lynch syndrome: a literature review and analytical observational retrospective cohort study.
    Adam F; Fluri M; Scherz A; Rabaglio M
    BMC Med Genomics; 2023 Jan; 16(1):7. PubMed ID: 36647026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next step in molecular genetics of hereditary breast/ovarian cancer: Multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance.
    Castillo-Guardiola V; Rosado-Jiménez L; Sarabia-Meseguer MD; Marín-Vera M; Macías-Cerrolaza JA; García-Hernández R; Zafra-Poves M; Sánchez-Henarejos P; Moreno-Locubiche MÁ; Cuevas-Tortosa E; Arnaldos-Carrillo M; Ayala de la Peña F; Alonso-Romero JL; Noguera-Velasco JA; Ruiz-Espejo F
    Eur J Med Genet; 2022 Apr; 65(4):104468. PubMed ID: 35245693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racial and Ethnic Differences in BRCA1/2 and Multigene Panel Testing Among Young Breast Cancer Patients.
    Jones T; Trivedi MS; Jiang X; Silverman T; Underhill M; Chung WK; Kukafka R; Crew KD
    J Cancer Educ; 2021 Jun; 36(3):463-469. PubMed ID: 31802423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of pathogenic variants and variants of unknown significance in patients at high risk of breast cancer: A systematic review and meta-analysis of gene-panel data.
    van Marcke C; Collard A; Vikkula M; Duhoux FP
    Crit Rev Oncol Hematol; 2018 Dec; 132():138-144. PubMed ID: 30447919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.